|
|
| | SELICICLIB Basic information |
| Product Name: | SELICICLIB | | Synonyms: | 2-[[9-(1-methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-Butanol;(+/-)-ROSCOVITINE;2-((6-(Benzylamino)-9-isopropyl-9H-purin-2-yl)amino)butan-1-ol;(Rac)-Roscovitine;1-Butanol, 2-[[9-(1-methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]- | | CAS: | 186692-44-4 | | MF: | C19H26N6O | | MW: | 354.45 | | EINECS: | | | Product Categories: | | | Mol File: | 186692-44-4.mol |  |
| | SELICICLIB Chemical Properties |
| Boiling point | 577.5±60.0 °C(Predicted) | | density | 1.25 | | pka | 14.56±0.10(Predicted) |
| | SELICICLIB Usage And Synthesis |
| Uses | (Rac)-Roscovitine ((Rac)-Seliciclib) is a selective cyclin-dependent kinases (CDKs) inhibitor. (Rac)-Roscovitine binds to the active sites of CDKs competitively with ATP, inhibiting the phosphorylation activity of CDKs. (Rac)-Roscovitine induces apoptosis in cancer cells. (Rac)-Roscovitine is promising for research of cancers or other diseases associated with CDK dysregulation, such as neurodegenerative diseases, cardiac disorders, viral and protozoan infections, glomerulonephritis, and chronic inflammation[1]. | | References | [1] Jorda R, et al. Pyrazolo[4,3-d]pyrimidine bioisostere of roscovitine: evaluation of a novel selective inhibitor of cyclin-dependent kinases with antiproliferative activity. J Med Chem. 2011 Apr 28;54(8):2980-93. |
| | SELICICLIB Preparation Products And Raw materials |
|